1419075-88-9 Usage
Uses
Used in Pharmaceutical Industry:
4-(1,3,4-Oxadiazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester is used as a potential pharmaceutical agent for its possible wide range of biological activities. 4-(1,3,4-Oxadiazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester's structure, including the piperidinecarboxylic acid and the 1,3,4-oxadiazole ring, suggests it may exhibit properties such as anti-inflammatory, analgesic, and antipsychotic effects. These properties are commonly sought after in drug development for the treatment of various conditions.
Further research and testing are required to explore the specific applications and therapeutic potential of 4-(1,3,4-Oxadiazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester, as well as to understand its safety and efficacy profile. The presence of the 1,3,4-oxadiazole ring, which is found in many bioactive molecules, indicates that 4-(1,3,4-Oxadiazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester could be a promising candidate for the development of new drugs with diverse pharmacological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1419075-88-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,9,0,7 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1419075-88:
(9*1)+(8*4)+(7*1)+(6*9)+(5*0)+(4*7)+(3*5)+(2*8)+(1*8)=169
169 % 10 = 9
So 1419075-88-9 is a valid CAS Registry Number.
1419075-88-9Relevant academic research and scientific papers
N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE
-
Page/Page column 111; 112, (2015/07/07)
Compounds of the formula (I) in which R, R1 and R3 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA
-
Page/Page column 76, (2013/06/27)
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
